Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1975 2
1976 1
1978 2
1980 2
1982 1
1984 2
1985 5
1986 2
1987 5
1988 1
1989 5
1990 1
1991 3
1995 1
1998 3
2001 3
2002 3
2003 1
2004 1
2006 2
2007 3
2008 2
2009 2
2010 3
2011 3
2012 4
2013 9
2014 6
2015 5
2016 1
2017 1
2018 6
2019 6
2020 10
2021 10
2022 12
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

116 results
Results by year
Filters applied: . Clear all
Page 1
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, McJannett MM, Stockler MR, Violet JA, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Hofman MS, et al. Among authors: francis rj. Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11. Lancet. 2021. PMID: 33581798 Clinical Trial.
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong LM, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Link E, Marusic P, Matera A, Herschtal A, Iravani A, Hicks RJ, Williams S, Murphy DG; proPSMA Study Group Collaborators. Hofman MS, et al. Among authors: francis rj. Lancet. 2020 Apr 11;395(10231):1208-1216. doi: 10.1016/S0140-6736(20)30314-7. Epub 2020 Mar 22. Lancet. 2020. PMID: 32209449 Clinical Trial.
TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).
Hofman MS, Emmett L, Violet J, Y Zhang A, Lawrence NJ, Stockler M, Francis RJ, Iravani A, Williams S, Azad A, Martin A, McJannett M; ANZUP TheraP team; Davis ID. Hofman MS, et al. Among authors: francis rj. BJU Int. 2019 Nov;124 Suppl 1:5-13. doi: 10.1111/bju.14876. Epub 2019 Oct 22. BJU Int. 2019. PMID: 31638341 Free article. Clinical Trial.
Mycobacterium mimicking metastatic melanoma.
Teh RW, Feeney K, Francis RJ, Phillips M, Millward MJ. Teh RW, et al. Among authors: francis rj. Intern Med J. 2013 Dec;43(12):1342-6. doi: 10.1111/imj.12209. Intern Med J. 2013. PMID: 24330366 Review.
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, Francis RJ, Zhang AY, Scott AM, Lee ST, Azad AA, McJannett MM, Stockler MR, Williams SG, Davis ID, Hofman MS; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Buteau JP, et al. Among authors: francis rj. Lancet Oncol. 2022 Nov;23(11):1389-1397. doi: 10.1016/S1470-2045(22)00605-2. Epub 2022 Oct 16. Lancet Oncol. 2022. PMID: 36261050 Clinical Trial.
Clinical pharmacology of cilazapril.
Kleinbloesem CH, van Brummelen P, Francis RJ, Wiegand UW. Kleinbloesem CH, et al. Among authors: francis rj. Drugs. 1991;41 Suppl 1:3-10. doi: 10.2165/00003495-199100411-00003. Drugs. 1991. PMID: 1712269 Review.
Clinical pharmacology of cilazapril.
Kleinbloesem CH, Van Brummelen P, Francis RJ, Wiegand UW. Kleinbloesem CH, et al. Among authors: francis rj. Am J Med. 1989 Dec 26;87(6B):45S-49S. doi: 10.1016/0002-9343(89)90092-2. Am J Med. 1989. PMID: 2532460 Review.
Considerations for Imaging of Malignant Pleural Mesothelioma: A Consensus Statement from the International Mesothelioma Interest Group.
Katz SI, Straus CM, Roshkovan L, Blyth KG, Frauenfelder T, Gill RR, Lalezari F, Erasmus J, Nowak AK, Gerbaudo VH, Francis RJ, Armato SG 3rd. Katz SI, et al. Among authors: francis rj. J Thorac Oncol. 2022 Dec 20:S1556-0864(22)01928-1. doi: 10.1016/j.jtho.2022.11.018. Online ahead of print. J Thorac Oncol. 2022. PMID: 36549385 Review.
116 results